BRAF/MEKi
6 abstracts
Abstract
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: Propensity score–matched recurrence-free, distant metastasis-free, and overall survival analysis.Org: Leiden University Medical Center, Maastricht University Medical Centre, Zuyderland MC, The Netherlands Cancer Institute, University Medical Center of Utrecht,
Abstract
Genomics to select treatment for patients (pts) with metastatic cancer: Final analysis of Molecular Tumor Board (MTB) evaluations in the ROME trial.Org: IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy, Department of Clinical and Molecular Medicine, Oncology Unit, Sant’ Andrea University Hospital, Sapienza University of Rome, Roma, Italy, Dipartimento di Eccellenza in Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Napoli UOC PATOLOGIA CLINICA - Ospedale San Giovanni Addolorata, Roma, Rome, Italy, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy,
Abstract
Nature and management of melanoma recurrences following adjuvant anti-PD-1 (PD1) therapy.Org: Melanoma Institute Australia, Netherlands Cancer Institute (NKI), Department of Dermatology, APHP St Louis, Alfred Health,
Abstract
Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: Results from the observational study GEM1801.Org: Hospital Universitario San Pedro de Alcántara, Unidad Intercentros de Oncología, Hospitales Universitarios Regional y Virgen de la Victoria (HURyVV), Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Universitari Vall d’Hebron y Vall Hebrón Institute of Oncology (VHIO),
Abstract
Investigating the patterns of treatment failure in patients with advanced stage III and IV melanoma receiving adjuvant therapy.Org: Massachusetts General Hospital, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Surgical Oncology, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Massachusetts General Hospital/Harvard Medical School, Dana-Farber Cancer Institute,
Abstract
Factors associated with overall survival in patients with melanoma leptomeningeal disease (M-LMD): A single institution retrospective review.Org: H. Lee Moffitt Cancer Center and Research Institute, Medical College of Georgia, Augusta, GA, Moffitt Cancer Center,